Brand company tactics aimed at keeping biosimilars off the market could have the unintended consequence of undercutting public support for innovation, in addition to squelching the fledgling biosimilar industry, US FDA Commissioner Scott Gottlieb believes.
In a July 18 speech at the Brookings Institution, Gottlieb once again harshly criticized contracting and rebating practices, as well...








